SEC Filing Analysis: HERON THERAPEUTICS, INC. /DE/ (HRTX)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The transaction is a routine, non-discretionary vesting of Restricted Stock Units (RSUs) by the company's CFO, not an open-market purchase, and carries no investment signal.
• Market Impact: Neutral. The event is financially immaterial and represents a negligible dilution for existing shareholders.

Company Information

Field	Value
Company	HERON THERAPEUTICS, INC. /DE/
Ticker Symbol	HRTX
CIK	0000818033
Industry	PHARMACEUTICAL PREPARATIONS

Insider Information

Field	Value
Name	Duarte Ira
CIK	0001488864
Title/Position	EVP, Chief Financial Officer
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-10-19
Transaction Code	M (Conversion of derivative security)
Security Type	Common Stock acquired from RSU vesting
Shares Involved	3,874
Price Per Share	$0.00
Total Value	$0
Shares Owned After	168,092
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0
% of Market Cap	0.00%
Shares Transacted	3,874
% of Shares Outstanding	0.0021%
Post-Transaction Ownership	168,092 shares (0.092% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a small-cap company with a $240 million market capitalization, this $0 value transaction is entirely immaterial.
• Ownership Concentration: The CFO's post-transaction ownership of 0.092% is not a significant stake in the company.
• Dilution Impact: The issuance of 3,874 new shares represents a negligible dilution of 0.0021% to existing shareholders, which is an expected part of equity-based compensation plans.
• Transaction Significance: The transaction's size relative to both market cap (0%) and shares outstanding (<0.01%) is well below any threshold for significance. It is a routine administrative event.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This is a non-market event reflecting the vesting of a prior compensation award. It does not signal any change in the insider's sentiment or a new investment decision.

Volume & Sentiment

• Expected Volume Impact: None. The transaction did not occur on the open market.
• Sentiment Indicator: Neutral. The market typically disregards routine RSU vesting events as they are pre-scheduled and part of standard executive compensation.

Investment Insights

Positive Market Indicators

• None. This transaction does not provide any positive market signals.

Risk Factors

• None. This transaction does not introduce any new risk factors.

Key Takeaways

1. Routine Compensation: This is a standard vesting of RSUs, part of the CFO's compensation package, not a discretionary trade.
2. No Market Signal: The transaction should not be interpreted as the insider's view on the company's future prospects.
3. Immaterial Impact: The financial impact on the company and its shareholders is negligible from a dilution and valuation perspective.

Additional Context

Transaction Notes

• The 'M' transaction code confirms the acquisition of common stock was the result of a conversion or exercise, in this case, the vesting of RSUs.
• Footnote 2 clarifies that the RSUs are part of a grant from January 19, 2024, that vests in 16 quarterly installments, confirming the routine and scheduled nature of this event.